非维生素K拮抗剂口服抗凝药与华法林在亚洲房颤患者中的比较:随机试验与真实世界研究的Meta分析
该Meta分析纳入5项NOAC随机试验和21项观察性队列,比较NOACs与华法林在亚洲房颤患者中的疗效与安全性。结果显示,NOACs在降低卒中或系统性栓塞、全因死亡、大出血及颅内出血风险方面均优于华法林,真实世界数据还显示其降低缺血性卒中、心肌梗死和消化道出血风险。亚组分析显示结果不受NOAC类型和剂量影响。
要点
- NOACs较华法林降低亚洲房颤患者卒中或系统性栓塞风险(随机试验RR 0.73,真实世界RR 0.75)。
- NOACs较华法林降低大出血和颅内出血风险,真实世界数据还显示降低消化道出血风险。
- NOACs的获益不受NOAC类型和剂量影响。
核心结论
- 在亚洲房颤患者中,NOACs不劣于华法林,且无论NOAC类型和剂量如何,结果一致。
研究设计与样本
- Meta分析,纳入5项NOAC随机试验和21项观察性队列研究,检索PubMed和Embase数据库2009年1月至2019年2月。
主要发现
- 随机试验中,NOACs较华法林降低卒中或系统性栓塞风险(RR 0.73;95%CI 0.59-0.90)、全因死亡(RR 0.83;95%CI 0.73-0.95)、大出血(RR 0.59;95%CI 0.48-0.72)和颅内出血(RR 0.36;95%CI 0.26-0.49)。
- 真实世界数据中,NOACs较华法林降低卒中或系统性栓塞(RR 0.75;95%CI 0.68-0.82)、缺血性卒中(RR 0.70;95%CI 0.59-0.83)、心肌梗死(RR 0.74;95%CI 0.58-0.93)、全因死亡(RR 0.67;95%CI 0.59-0.77)、大出血(RR 0.63;95%CI 0.55-0.73)、颅内出血(RR 0.50;95%CI 0.43-0.59)和消化道出血(RR 0.65;95%CI 0.51-0.84)。
- 亚组分析基于NOAC类型和剂量,结果未发生变化。
临床怎么用
- 亚洲房颤患者卒中预防可优先考虑NOACs,其疗效和安全性优于华法林。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Several randomized trials and real-world studies have reported the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in Asian patients with atrial fibrillation; and therefore, this meta-analysis was aimed to compare the effects of NOACs with warfarin for atrial fibrillation stroke prevention in Asians. Methods- The PubMed and Embase databases were searched from January 2009 to February 2019 for studies on comparisons of NOACs versus warfarin in Asians. Risk ratios (RRs) with 95% CIs were pooled using a random-effects model. Results- Five NOAC trials and 21 observational cohorts were included. For the NOAC trials, compared with warfarin, NOACs was associated with reduced risks of stroke or systemic embolism (RR, 0.73; 95% CI, 0.59-0.90), all-cause death (RR, 0.83; 95% CI, 0.73-0.95), major bleeding (RR, 0.59; 95% CI, 0.48-0.72), and intracranial bleeding (RR, 0.36; 95% CI, 0.26-0.49). For the real-world data, compared with warfarin, NOACs was associated with decreased rates of stroke or systemic embolism (RR, 0.75; 95% CI, 0.68-0.82), ischemic stroke (RR, 0.70; 95% CI, 0.59-0.83), myocardial infarction (RR, 0.74; 95% CI, 0.58-0.93), all-cause death (RR, 0.67; 95% CI, 0.59-0.77), major bleeding (RR, 0.63; 95% CI, 0.55-0.73), intracranial bleeding (RR, 0.50; 95% CI, 0.43-0.59), and gastrointestinal bleeding (RR, 0.65; 95% CI, 0.51-0.84). The results did not change in the subgroup analyses based on the type and dose of NOACs. Conclusions- Based on published NOAC trials and real-world studies, the use of NOACs is noninferior to warfarin in Asians with atrial fibrillation irrespective of the NOAC type and dose.
引用
- Xue Z, Zhang H. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies. Stroke. 2019. PMID: 31422735. doi:10.1161/STROKEAHA.119.026054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。